BUSINESS MODEL
Next-Generation Cell Therapy or Drug Delivery Collaboration
MDimune is currently seeking partners for R&D collaborations that utilize the BioDrone™(CDVs) platform for next-generation cell therapies or targeted payload delivery.
R&D collaboration involves the development of CDVs tailored to customers' need (MDimune) and rigorous testing in a relevant model system (Partner). The current focus is on (1) the development of the next-generation cell therapy candidates and (2) novel bio-safe DDS (drug delivery system) enabled to deliver payloads of interest including siRNA, ASOs, mRNA and others,
The standard agreement includes the following:
- Upfront Payment, Development, Regulatory and Sales Milestones, and Royalties
- Other deal structures, including co-development or option-based transactions, will be considered
- R&D Funding to cover all expenses incurred by MDimune
